SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 31st, 2010 • Alseres Pharmaceuticals Inc /De • Pharmaceutical preparations • Delaware
THIS SECURITIES PURCHASE AGREEMENT (this “Agreement”), dated as of August 11, 2009, by and among Alseres Pharmaceuticals, Inc., a Delaware corporation with headquarters located at 239 South Street, Hopkinton, MA 01748 (the “Company”) and each investor identified on the signature pages hereto (individually, an “Investor” and collectively, the “Investors).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • March 31st, 2010 • Alseres Pharmaceuticals Inc /De • Pharmaceutical preparations • Delaware
The selling stockholders may from time to time pledge or grant a security interest in some or all of the shares of common stock owned by them and, if they default in the performance of their secured obligations, the pledgees or secured parties may offer and sell the shares of common stock from time to time under this prospectus after we have filed a supplement to this prospectus under Rule 424(b)(3) or other applicable provision of the Securities Act of 1933 supplementing or amending the list of selling stockholders to include the pledgee, transferee or other successors in interest as selling stockholders under this prospectus.
Confidential Materials omitted and filed separately with the Securities and Exchange Commission. Asterisks denote omissions.Alseres Pharmaceuticals Inc /De • March 31st, 2010 • Pharmaceutical preparations
Reference is made to the agreement between MDS Nordion, a division of MDS (Canada) Inc., and Alseres Pharmaceuticals Inc., (“ALSE”) dated the 9th day of August, 2000 as amended (the “Agreement”).
AMENDMENT NO. 1 TO LICENSE AGREEMENTLicense Agreement • March 31st, 2010 • Alseres Pharmaceuticals Inc /De • Pharmaceutical preparations • New York
THIS AMENDMENT (this “Amendment”) dated as of April 23, 2009 (“Amendment Effective Date”) is between Alseres Pharmaceuticals, Inc. (f/k/a Boston Life Sciences, Inc.), a Delaware corporation with offices at 85 Main Street, Hopkinton, MA 01748 (“Alseres”) and BioAxone Therapeutic Inc., a Canadian corporation with offices at 1100 Rene-Levesque West, 25th Floor, Montreal, QC H3B 5C9 Canada (“BA” and collectively with Alseres, the “Parties”).
